Clinical trial

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

NCT02779855

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-05-02

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2017-05-02Date precision: day

Registry last updated2026-03-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Ductal Carcinomaunresolved

Invasive Breast Carcinomaunresolved

Invasive Ductal Breast Carcinomaunresolved

Interventions

Talimogene laherparepvecBIOLOGICAL

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Amgencollaborator

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02779855 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.